<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAPTOPRIL AND HYDROCHLOROTHIAZIDE- captopril and hydrochlorothiazide tablet </strong><br>Mylan Phamaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_af2fd8d8-3f54-497e-a70a-fd47e5de9a8e"></a><a name="section-1"></a><p></p>
<h1>USE IN PREGNANCY</h1>
<p class="First"><span class="Bold">When used in pregnancy during the second and third trimesters, ACE Inhibitors can cause injury and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span> When pregnancy is detected, Captopril and Hydrochlorothiazide should be discontinued as soon as possible. <span class="Bold">See <a href="#i4i_section_id_fetal">WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_1cd3f00f-9ded-4ebb-872f-bfa5ede885ff"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Captopril and hydrochlorothiazide tablets, USP for oral administration combines two antihypertensive agents: captopril and hydrochlorothiazide. Catopril, the first of a new class of antihypertensive agents, is a specific competitive inhibitor of angiotensin I-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I to angiotensin II. Hydrochlorothiazide is a benzothiadiazide (thiazide) diuretic-antihypertensive.</p>
<p>Captopril, USP is a white to off-white crystalline powder that may have a slight sulfurous odor; it is soluble in water (approx. 160 mg/mL), methanol, and ethanol and sparingly soluble in chloroform and ethyl acetate.</p>
<p>Hydrochlorothiazide, USP is a white crystalline powder slightly soluble in water but freely soluble in sodium hydroxide solution.</p>
<p>Captopril is designated chemically as 1-[(2S)-3-Mercapto-2-methylpropionyl]-L-proline; Hydrochlorothiazide is 6-Chloro-3,4-dihydro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Their structural formulas are:</p>
<div class="Figure">
<a name="id680"></a><img alt="Structural Formulas" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d826812e-ede7-49e7-8384-29ec5b142ef3&amp;name=1ce0ed86-6073-4983-86bf-6d022e27ce7e-01.jpg">
</div>
<p>Captopril and Hydrochlorothiazide Tablets, USP are available for oral administration in four combinations of captopril with hydrochlorothiazide: 25 mg with 15 mg, 25 mg with 25 mg, 50 mg with 15 mg, and 50 mg with 25 mg. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose, pregelatinized starch, and sodium lauryl sulfate. The 25 mg/25 mg and 50 mg/25 mg tablets also contain the coloring agent FD&amp;C Yellow #6 Aluminum Lake.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e09f52f-eb7f-4b97-8642-d0e8e5beb983"></a><a name="section-2.1"></a><p></p>
<h2>Captopril</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff84baf5-c4b9-4ec9-a06c-b804511a7c72"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Mechanism of Action</span></h3>
<p class="First">The mechanism of action of captopril has not yet been fully elucidated. Its beneficial effects in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> appear to result primarily from suppression of the renin-angiotensin-aldosterone system. However, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
<p>Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. This inhibition has been demonstrated in both healthy human subjects and in animals by showing that the elevation of blood pressure caused by exogenously administered angiotensin I was attenuated or abolished by captopril. In animal studies, captopril did not alter the pressor responses to a number of other agents, including angiotensin II and norepinephrine, indicating specificity of action.</p>
<p>ACE is identical to "bradykininase", and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. Increased concentrations of bradykinin or prostaglandin E<span class="Sub">2</span> may also have a role in the therapeutic effect of captopril.</p>
<p>Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity (PRA), the latter resulting from loss of negative feedback on renin release caused by reduction in angiotensin II. The reduction of angiotensin II leads to decreased aldosterone secretion, and, as a result, small increases in serum potassium may occur along with sodium and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span>.</p>
<p>The antihypertensive effects persist for a longer period of time than does demonstrable inhibition of circulating ACE. It is not known whether the ACE present in vascular endothelium is inhibited longer than the ACE in circulating blood.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9381423e-b8ee-49b4-a871-ec8ff760df7f"></a><a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">Pharmacokinetics</span></h3>
<p class="First">After oral administration of therapeutic doses of captopril, rapid absorption occurs with peak blood levels at about one hour. The presence of food in the gastrointestinal tract reduces absorption by about 30 to 40 percent; captopril therefore should be given one hour before meals. Based on carbon-14 labeling, average minimal absorption is approximately 75 percent. In a 24-hour period, over 95 percent of the absorbed dose is eliminated in the urine; 40 to 50 percent is unchanged drug; most of the remainder is the disulfide dimer of captopril and captopril-cysteine disulfide.</p>
<p>Approximately 25 to 30 percent of the circulating drug is bound to plasma proteins. The apparent elimination half-life for total radioactivity in blood is probably less than three hours. An accurate determination of half-life of unchanged captopril is not, at present, possible, but it is probably less than two hours. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, however, retention of captopril occurs (see <a href="#i4i_dosage_admin_id_administration">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ebea177f-0a52-4e95-b435-f986cab5caa5"></a><a name="section-2.1.3"></a><p></p>
<h3><span class="Bold">Pharmacodynamics</span></h3>
<p class="First">Administration of captopril results in a reduction of peripheral arterial resistance in hypertensive patients with either no change, or an increase, in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>. There is an increase in renal blood flow following administration of captopril and glomerular filtration rate is usually unchanged. In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, significantly decreased peripheral (systemic vascular) resistance and blood pressure (afterload), reduced pulmonary capillary wedge pressure (preload) and pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and increased exercise tolerance time (ETT) have been demonstrated.</p>
<p>Reductions of blood pressure are usually maximal 60 to 90 minutes after oral administration of an individual dose of captopril. The duration of effect is dose related and is extended in the presence of a thiazide-type diuretic. The full effect of a given dose may not be attained for 6 to 8 weeks (see <a href="#i4i_dosage_admin_id_administration">DOSAGE AND ADMINISTRATION</a>). The blood pressure lowering effects of captopril and thiazide-type diuretics are additive. In contrast, captopril and beta-blockers have a less than additive effect.</p>
<p>Blood pressure is lowered to about the same extent in both standing and supine positions. Orthostatic effects and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> are infrequent but may occur in volume-depleted patients. Abrupt withdrawal of captopril has not been associated with a rapid increase in blood pressure.</p>
<p>Studies in rats and cats indicate that captopril does not cross the blood-brain barrier to any significant extent.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1caee95c-3261-4601-8c79-8dfa5b4da32b"></a><a name="section-2.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Thiazides affect the renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic potency.</p>
<p>Thiazides increase excretion of sodium and chloride in approximately equivalent amounts. Natriuresis causes a secondary loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.</p>
<p>The mechanism of the antihypertensive effect of thiazides is unknown. Thiazides do not affect normal blood pressure.</p>
<p>The mean plasma half-life of hydrochlorothiazide in fasted individuals has been reported to be approximately 2.5 hours.</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> occurs in two hours and the peak effect at about four hours. Its action persists for approximately six to twelve hours. Hydrochlorothiazide is eliminated rapidly by the kidney.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_646004cb-9d88-457c-8ca4-853223848f54"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Captopril and Hydrochlorothiazide tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The blood pressure lowering effects of captopril and thiazides are approximately additive.</p>
<p>This fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components.</p>
<p>When captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). Also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate.</p>
<p>Treatment may, therefore, be initiated with Captopril and Hydrochlorothiazide tablets 25 mg/15 mg once daily. Subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as Captopril and Hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see <a href="#i4i_dosage_admin_id_administration">DOSAGE AND ADMINISTRATION</a>).</p>
<p>In using Captopril and Hydrochlorothiazide, consideration should be given to the risk of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p>Captopril and Hydrochlorothiazide may be used for patients with normal renal function, in whom the risk is relatively low. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, particularly those with collagen vascular disease, Captopril and Hydrochlorothiazide should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to other drug combinations.</p>
<p>ACE inhibitors (for which adequate data are available) cause a higher rate of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in black than in non-black patients (see <a href="#i4i_section_id_neck">WARNINGS: Captopril: Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_46018e1f-7e61-4ff7-8b50-819e30e0fdd3"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fecb207-99d7-4592-80b3-96a217827e45"></a><a name="section-4.1"></a><p></p>
<h2>Captopril</h2>
<p class="First">This product is contraindicated in patients who are hypersensitive to captopril or any other angiotensin-converting enzyme inhibitor (e.g., a patient who has experienced <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> during therapy with any other ACE inhibitor).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79da77e9-4079-46df-82a3-11cce4845fe9"></a><a name="section-4.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Hydrochlorothiazide is contraindicated in <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>. It is also contraindicated in patients who have previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to hydrochlorothiazide or other sulfonamide-derived drugs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_captopril"></a><a name="section-5.1"></a><p></p>
<h2>Captopril</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_603c5c89-358c-46c5-a698-3533d904add9"></a><a name="section-5.1.1"></a><p></p>
<h3><span class="Bold">Anaphylactoid and Possible Related Reactions</span></h3>
<p class="First">Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including captopril) may be subject to a variety of adverse reactions, some of them serious.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_neck"></a><a name="section-5.1.1.1"></a><p></p>
<h4><span class="Bold">Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been seen in patients treated with ACE inhibitors, including captopril. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> involves the tongue, glottis or larynx, airway obstruction may occur and be fatal. Emergency therapy, including but not necessarily limited to, subcutaneous administration of a 1:1000 solution of epinephrine should be promptly instituted.</p>
<p><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> confined to the face, mucous membranes of the mouth, lips and extremities has usually resolved with discontinuation of treatment; some cases required medical therapy. (See <a href="#i4i_info_patients_id_information">PRECAUTIONS: Information for Patients</a> and <a href="#i4i_section_id_captopril">ADVERSE REACTIONS: Captopril</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_intestinal"></a><a name="section-5.1.1.2"></a><p></p>
<h4><span class="Bold">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></h4>
<p class="First">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has been reported in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. The <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> should be included in the differential diagnosis of patients on ACE inhibitors presenting with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5998d5c8-944f-4ec3-8939-417e816ed163"></a><a name="section-5.1.1.3"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during desensitization</span></h4>
<p class="First">Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_membrane"></a><a name="section-5.1.1.4"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during membrane exposure</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_323f849b-e538-497e-8e3b-f1fd97b1946f"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt; 1000/mm<span class="Sup">3</span>) with myeloid hypoplasia has resulted from use of captopril. About half of the neutropenic patients developed systemic or oral cavity <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or other features of the syndrome of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is dependent on the clinical status of the patient:</p>
<p> In clinical trials in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> who have normal renal function (serum creatinine less than 1.6 mg/dL and no collagen vascular disease), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has been seen in one patient out of over 8,600 exposed.</p>
<p> In patients with some degree of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (serum creatinine at least 1.6 mg/dL) but no collagen vascular disease, the risk of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> in clinical trials was about 1 per 500, a frequency over 15 times that for <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span>. Daily doses of captopril were relatively high in these patients, particularly in view of their diminished renal function. In foreign marketing experience in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, use of allopurinol concomitantly with captopril has been associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> but this association has not appeared in U.S. reports.</p>
<p> In patients with collagen vascular diseases (e.g., <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>, <span class="product-label-link" type="condition" conceptid="134442" conceptname="Systemic sclerosis">scleroderma</span>) and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> occurred in 3.7 percent of patients in clinical trials.</p>
<p> While none of the over 750 patients in formal clinical trials of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> developed <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, it has occurred during the subsequent clinical experience. About half of the reported cases had serum creatinine ≥ 1.6 mg/dL and more than 75 percent were in patients also receiving procainamide. In <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, it appears that the same risk factors for <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> are present.</p>
<p>The <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> has usually been detected within three months after captopril was started. <span class="product-label-link" type="condition" conceptid="4043761" conceptname="Bone marrow examination">Bone marrow examinations</span> in patients with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> consistently showed myeloid hypoplasia, frequently accompanied by erythroid hypoplasia and decreased numbers of megakaryocytes (e.g., hypoplastic bone marrow and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>); <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> were sometimes seen.</p>
<p>In general, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> returned to normal in about two weeks after captopril was discontinued, and serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were limited to clinically complex patients. About 13 percent of the cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or immunosuppressant therapy, or a combination of these complicating factors.</p>
<p><span class="Bold">Evaluation of the hypertensive or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> patient should always include assessment of renal function.</span></p>
<p>If captopril is used in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, white blood cell and differential counts should be evaluated prior to starting treatment and at approximately two-week intervals for about three months, then periodically.</p>
<p>In patients with collagen vascular disease or who are exposed to other drugs known to affect the white cells or immune response, particularly when there is <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, captopril should be used only after an assessment of benefit and risk, and then with caution.</p>
<p>All patients treated with captopril should be told to report any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>). If <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is suspected, white cell counts should be performed without delay.</p>
<p>Since discontinuation of captopril and other drugs has generally led to prompt return of the white count to normal, upon confirmation of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (neutrophil count &lt; 1000/mm<span class="Sup">3</span>) the physician should withdraw captopril and closely follow the patient's course.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7b8654e-b9db-4672-8594-e461de7c087e"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></span></h3>
<p class="First">Total urinary proteins greater than 1 g per day were seen in about 0.7 percent of patients receiving captopril. About 90 percent of affected patients had evidence of prior <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or received relatively high doses of captopril (in excess of 150 mg/day), or both. The <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> occurred in about one-fifth of proteinuric patients. In most cases, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> subsided or cleared within six months whether or not captopril was continued. Parameters of renal function, such as BUN and creatinine, were seldom altered in the patients with <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6bd523c-b555-4d83-b20c-3d292812da89"></a><a name="section-5.1.4"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></h3>
<p class="First">Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> was rarely seen in hypertensive patients but is a possible consequence of captopril use in salt/volume depleted persons (such as those treated vigorously with diuretics), patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or those patients undergoing renal dialysis. (See <a href="#i4i_interactions_id_interactions">PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fetal"></a><a name="section-5.1.5"></a><p></p>
<h3><span class="Bold">Fetal/Neonatal Morbidity and Mortality</span></h3>
<p class="First">ACE inhibitors can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.</p>
<p>The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> has also been reported, presumably resulting from decreased fetal renal function; <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> in this setting has been associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.</p>
<p>These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of captopril as soon as possible.</p>
<p>Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, captopril should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics">in utero</span> exposure to ACE inhibitors should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. While captopril may be removed from the adult circulation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective for removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation.</p>
<p>When captopril was given to rabbits at doses about 0.8 to 70 times (on a mg/kg basis) the maximum recommended human dose, low incidences of craniofacial malformations were seen. No teratogenic effects of captopril were seen in studies of pregnant rats and hamsters. On a mg/kg basis, the doses used were up to 150 times (in hamsters) and 625 times (in rats) the maximum recommended human dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ec46460-662c-413f-84d5-b52977f9faed"></a><a name="section-5.1.6"></a><p></p>
<h3><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></span></h3>
<p class="First">Rarely, ACE Inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> and (sometimes) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_hydrochlorothiazide"></a><a name="section-5.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
<p>Sensitivity reactions may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>The possibility of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.</p>
<p>In general, lithium should not be given with diuretics (see <a href="#i4i_section_id_hydrochlorothiazide">PRECAUTIONS: Drug Interactions: Hydrochlorothiazide</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_e9089855-2b5a-41d9-bc22-52baa8917193"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_general"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6edd13d-1af6-4b4f-af79-867dff4efc3a"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Captopril</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f9d2926-7826-425a-914a-2a7cfe1b41cf"></a><a name="section-6.1.1.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></h4>
<p class="First">Some patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, particularly those with severe <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, have developed increases in BUN and serum creatinine after reduction of blood pressure with captopril. Captopril dosage reduction and/or discontinuation of diuretic may be required. For some of these patients, it may not be possible to normalize blood pressure and maintain adequate renal perfusion (see <a href="#i4i_clinical_pharmacology_id_pharmacology">CLINICAL PHARMACOLOGY</a>, <a href="#i4i_dosage_admin_id_administration">DOSAGE AND ADMINISTRATION</a>, <a href="#i4i_section_id_altered">ADVERSE REACTIONS: Altered Laboratory Findings</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ebc145e-33eb-49e0-86f5-46903d26e7c6"></a><a name="section-6.1.1.2"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></h4>
<p class="First">Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including captopril. When treated with ACE inhibitors, patients at risk for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include those with: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; and those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or other drugs associated with increases in serum potassium. (See <a href="#i4i_info_patients_id_information">PRECAUTIONS: Information for Patients</a> and <a href="#i4i_section_id_captopril">Drug Interactions: Captopril</a>; <a href="#i4i_section_id_altered">ADVERSE REACTIONS: Altered Laboratory Findings</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cough"></a><a name="section-6.1.1.3"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></h4>
<p class="First">Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dbb651f3-8c60-4b0c-afc4-2c6e74426c2e"></a><a name="section-6.1.1.4"></a><p></p>
<h4><span class="Bold">Surgery/Anesthesia</span></h4>
<p class="First">In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, captopril will block angiotensin II formation secondary to compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_hemodialysis"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Hemodialysis</span></h3>
<p class="First">Recent clinical observations have shown an association of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>-like (anaphylactoid) reactions during hemodialysis with high-flux dialysis membranes (e.g., AN69) in patients receiving ACE inhibitors as medication. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of medication. (See <a href="#i4i_section_id_membrane">WARNINGS: Captopril: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> during membrane exposure</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_hydro"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals.</p>
<p>All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, namely: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> may include: dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, or when severe cirrhosis is present. Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> can sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>). Because captopril reduces the production of aldosterone, concomitant therapy with captopril reduces the diuretic-induced <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Fewer patients may require potassium supplements and/or foods with a high potassium content (see <a href="#i4i_section_id_500e99bc-0efc-4b39-ba6e-15c5d5863bbf">Drug Interactions: Captopril: Agents Increasing Serum Potassium</a>).</p>
<p>Any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>). Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">Latent diabetes</span> mellitus may become manifest during thiazide administration.</p>
<p>The antihypertensive effect of thiazide diuretics may be enhanced in the postsympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, as indicated by a rising nonprotein nitrogen or blood urea nitrogen (BUN), a careful reappraisal of therapy is necessary with consideration given to withholding or discontinuing diuretic therapy.</p>
<p>Thiazides may decrease serum PBI levels without signs of thyroid disturbance.</p>
<p>Calcium excretion is decreased by thiazides. Pathological changes in the parathyroid gland with <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> and <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span> have been observed in a few patients on prolonged thiazide therapy. The common complications of <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> such as renal lithiasis, bone resorption, and <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span> have not been seen. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_information"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised to immediately report to their physician any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (e.g., <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, eyes, lips, tongue, larynx and extremities; difficulty in swallowing or breathing; <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>) and to discontinue therapy. (See <a href="#i4i_section_id_neck">WARNINGS: Captopril: Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a>.)</p>
<p>Patients should be told to report promptly any indication of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (e.g., <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), which may be a sign of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or of progressive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> which might be related to <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> and <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>.</p>
<p>All patients should be cautioned that excessive perspiration and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume. Other causes of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> such as <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may also lead to a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>; patients should be advised to consult with the physician.</p>
<p>Patients should be advised not to use potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes without consulting their physician. (See <a href="#i4i_precautions_general_id_general">PRECAUTIONS: General</a> and <a href="#i4i_section_id_captopril">Drug Interactions: Captopril</a>; <a href="#i4i_section_id_captopril">ADVERSE REACTIONS: Captopril</a>.)</p>
<p>Patients should be warned against interruption or discontinuation of medication unless instructed by the physician.</p>
<p><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> patients on captopril therapy should be cautioned against rapid increases in physical activity.</p>
<p>Patients should be informed that Captopril and Hydrochlorothiazide tablets should be taken one hour before meals (see <a href="#i4i_dosage_admin_id_administration">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d89ba558-0334-4a77-9634-369673f77673"></a><a name="section-6.3"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_13fd114e-f212-4f89-9505-a12e5dfafcd4"></a><a name="section-6.4"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Serum electrolyte levels should be regularly monitored (see <a href="#i4i_section_id_captopril">WARNINGS: Captopril</a> and <a href="#i4i_section_id_hydrochlorothiazide">Hydrochlorothiazide</a>; <a href="#i4i_section_id_hydro">PRECAUTIONS: General: Hydrochlorothiazide</a>).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_interactions"></a><a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_500e99bc-0efc-4b39-ba6e-15c5d5863bbf"></a><a name="section-6.5.1"></a><p></p>
<h3><span class="Bold">Captopril</span></h3>
<p class="First"><span class="Italics">Hypotension—Patients On Diuretic Therapy</span>: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restrictions or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.</p>
<p>The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril or initiating therapy with small doses (6.25 or 12.5 mg). Alternatively, provide medical supervision for at least one hour after the initial dose. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in a supine position and, if necessary, receive an intravenous infusion of normal saline. This transient hypotensive response is not a contraindication to further doses which can be given without difficulty once the blood pressure has increased after volume expansion.</p>
<p><span class="Italics">Agents Having Vasodilator Activity</span>: Data on the effect of concomitant use of other vasodilators in patients receiving captopril for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> are not available; therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril. If resumed during captopril therapy, such agents should be administered cautiously, and perhaps at lower dosage.</p>
<p><span class="Italics">Agents Causing Renin Release</span>: Captopril's effect will be augmented by antihypertensive agents that cause renin release. For example, diuretics (e.g., thiazides) may activate the renin-angiotensin-aldosterone system.</p>
<p><span class="Italics">Agents Affecting Sympathetic Activity</span>: The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving captopril alone or with diuretics. Therefore, agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution. Beta-adrenergic blocking drugs add some further antihypertensive effect to captopril, but the overall response is less than additive.</p>
<p><span class="Italics">Agents Increasing Serum Potassium:</span>Since captopril decreases aldosterone production, elevation of serum potassium may occur. Potassium-sparing diuretics such as spironolactone, triamterene, or amiloride, or potassium supplements, should be given only for documented <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and then with caution, since they may lead to a significant increase of serum potassium. Salt substitutes containing potassium should also be used with caution.</p>
<p><span class="Italics">Inhibitors Of Endogenous Prostaglandin Synthesis:</span> It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Other nonsteroidal anti-inflammatory agents (e.g., aspirin) may also have this effect.</p>
<p><span class="Italics">Lithium</span>: Increased serum lithium levels and symptoms of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended. If a diuretic is also used, it may increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> (see <a href="#i4i_section_id_373baee6-d2cd-4759-97b1-7475eea17d3e">PRECAUTIONS: Drug Interactions: Hydrochlorothiazide: Lithium</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_373baee6-d2cd-4759-97b1-7475eea17d3e"></a><a name="section-6.5.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">When administered concurrently the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics">Alcohol, Barbiturates, or Narcotics:</span> potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics">Amphotericin B, Corticosteroids, or Corticotropin (ACTH):</span> may intensify <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Monitor potassium levels; use potassium replacements if necessary.</p>
<p><span class="Italics">Anticoagulants (Oral):</span> dosage adjustments of anticoagulant medication may be necessary since hydrochlorothiazide may decrease their effects.</p>
<p><span class="Italics">Antigout Medications:</span> dosage adjustments of antigout medication may be necessary since hydrochlorothiazide may raise the level of blood uric acid.</p>
<p><span class="Italics">Other Antihypertensive Medications (e.g., Ganglionic or Peripheral Adrenergic Blocking Agents):</span> dosage adjustments may be necessary since hydrochlorothiazide may potentiate their effects.</p>
<p><span class="Italics">Antidiabetic Drugs (Oral Agents and Insulin):</span> since thiazides may elevate blood glucose levels, dosage adjustments of antidiabetic agents may be necessary.</p>
<p><span class="Italics">Calcium Salts:</span> Increased serum calcium levels due to decreased excretion may occur. If calcium must be prescribed, monitor serum calcium levels and adjust calcium dosage accordingly.</p>
<p><span class="Italics">Cardiac Glycosides:</span> enhanced possibility of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis toxicity</span> associated with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Monitor potassium levels (see <a href="#i4i_section_id_captopril">PRECAUTIONS: Drug Interactions: Captopril</a>).</p>
<p><span class="Italics">Cholestyramine and Colestipol Resins:</span> Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.</p>
<p><span class="Italics">Diazoxide:</span> enhanced hyperglycemic, hyperuricemic, and antihypertensive effects. Be cognizant of possible interaction; monitor blood glucose and serum uric acid levels.</p>
<p><span class="Italics">Lithium:</span> diuretic agents reduce the renal clearance of lithium and increase the risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. These drugs should be coadministered with caution and frequent monitoring of serum lithium levels is recommended (see <a href="#i4i_section_id_500e99bc-0efc-4b39-ba6e-15c5d5863bbf">PRECAUTIONS: Drug Interactions: Captopril: Lithium</a>).</p>
<p><span class="Italics">MAO Inhibitors:</span> dosage adjustments of one or both agents may be necessary since hypotensive effects are enhanced.</p>
<p><span class="Italics">Nondepolarizing Muscle Relaxants, Preanesthetics and Anesthetics Used in Surgery (e.g., Tubocurarine Chloride and Gallamine Triethiodide):</span> effects of these agents may be potentiated; dosage adjustments may be required. Monitor and correct any fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span> prior to surgery if feasible.</p>
<p><span class="Italics">Nonsteroidal Anti-inflammatory Agents:</span> in some patients, the administration of a nonsteroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effect of loop, potassium-sparing or thiazide diuretics. Therefore, when hydrochlorothiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
<p><span class="Italics">Methenamine:</span> possible decreased effectiveness due to alkalinization of the urine.</p>
<p><span class="Italics">Pressor Amines (e.g., Norepinephrine):</span> decreased arterial responsiveness, but not sufficient to preclude effectiveness of the pressor agent for therapeutic use. Use caution in patients taking both medications who undergo surgery. Administer preanesthetic and anesthetic agents in reduced dosage, and if possible, discontinue hydrochlorothiazide therapy one week prior to surgery.</p>
<p><span class="Italics">Probenecid or Sulfinpyrazone:</span> increased dosage of these agents may be necessary since hydrochlorothiazide may have hyperuricemic effects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_1196cc1c-df5b-4e36-9998-e50ca4f275a2"></a><a name="section-6.6"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e01cc946-fe17-4fc4-8621-f0f5ae0b26f1"></a><a name="section-6.6.1"></a><p></p>
<h3><span class="Bold">Captopril</span></h3>
<p class="First">Captopril may cause a false-positive urine test for acetone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24643189-e9c3-406f-a078-8abcc1a230aa"></a><a name="section-6.6.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Hydrochlorothiazide may cause diagnostic interference of the bentiromide test.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_53c88a29-1524-40f2-83d3-8453ee9fe3b2"></a><a name="section-6.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity and fertility studies have not been conducted with captopril and hydrochlorothiazide tablets, however, in animals they have been conducted with the individual components as noted below. Mutagenecity studies indicate that captopril in a 2:1 combination with hydrochlorothiazide was not mutagenic or clastogenic, with or without metabolic activation, in the following <span class="Italics">in vitro</span> assays: 1) Ames reverse-mutation in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span>; 2) forward mutation study in <span class="Italics">Saccharomyces pombe</span>; 3) mitotic gene conversion test in <span class="Italics">Saccharomyces cerevisiae</span>; and 4) sister-chromatid-exchange study in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>.</p>
<p>In a cytogenetics study using human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, there were no increases in chromosomal abnormalities without metabolic activation, nor with metabolic activation at 28 hours post-treatment. A statistically significant increase was found at 22 hours with metabolic activation at the three concentrations tested (captopril/hydrochlorothiazide in a 2:1 combination at 5, 25, 50 mcg/mL total weight); however, there was no dose response, and the difference is probably attributable to the unusual absence of any abnormalities in the negative-control cultures in this test.</p>
<p>In an oral micronucleus study in mice, the captopril/hydrochlorothiazide combination (2:1 mixture at 2500 mg/kg total weight) was not genotoxic.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4abede9a-6667-4890-9d92-12edab63ded4"></a><a name="section-6.7.1"></a><p></p>
<h3><span class="Bold">Captopril</span></h3>
<p class="First">Two-year studies with doses of 50 to 1350 mg/kg/day in mice and rats failed to show any evidence of carcinogenic potential.</p>
<p>Studies in rats have revealed no impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_25bf7740-9b49-40f5-9a21-4171409f148a"></a><a name="section-6.7.2"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic in <span class="Italics">in vitro</span> assays using <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537 and TA 1538 of <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (Ames assay) and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics">in vivo assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the Drosophilia</span> sex linked recessive lethal trait gene. Positive test results were obtained only in the <span class="Italics">in vitro</span> CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 mcg/mL, and in the <span class="Italics">Aspergillus nidulans</span> non-disjunction assay at an unspecified concentration.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to conception and throughout gestation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_487c7e8a-9ae2-444f-b5c2-538a20f3533d"></a><a name="section-6.8"></a><p></p>
<h2>Animal Toxicology</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a12b60c-782f-41ef-95fa-ba64934a30b9"></a><a name="section-6.8.1"></a><p></p>
<h3><span class="Bold">Captopril</span></h3>
<p class="First">Chronic oral toxicity studies were conducted in rats (2 years), dogs (47 weeks; 1 year), mice (2 years), and monkeys (1 year). Significant drug-related toxicity included effects on hematopoiesis, renal toxicity, erosion/ulceration of the stomach, and variation of retinal blood vessels.</p>
<p>Reductions in hemoglobin and/or hematocrit values were seen in mice, rats, and monkeys at doses 50 to 150 times the maximum recommended human dose (MRHD). <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and bone marrow suppression occurred in dogs at doses 8 to 30 times MRHD. The reductions in hemoglobin and hematocrit values in rats and mice were only significant at 1 year and returned to normal with continued dosing by the end of the study. Marked <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was seen at all dose levels (8 to 30 times MRHD) in dogs, whereas moderate to marked <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> was noted only at 15 and 30 times MRHD and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> at 30 times MRHD. The <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> could be reversed upon discontinuation of dosing. Bone marrow suppression occurred to a varying degree, being associated only with dogs that died or were sacrificed in a moribund condition in the 1 year study. However, in the 47-week study at a dose 30 times MRHD, bone marrow suppression was found to be reversible upon continued drug administration.</p>
<p>Captopril caused <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> of the juxtaglomerular apparatus of the kidneys at doses 7 to 200 times the MRHD in rats and mice, at 20 to 60 times MRHD in monkeys, and at 30 times the MRHD in dogs.</p>
<p><span class="product-label-link" type="condition" conceptid="4341235" conceptname="Multiple gastric erosions">Gastric erosions</span>/ulcerations were increased in incidence at 20 and 200 times MRHD in male rats and at 30 and 65 times MRHD in dogs and monkeys, respectively. Rabbits developed gastric and <span class="product-label-link" type="condition" conceptid="195002" conceptname="Ulceration of intestine">intestinal ulcers</span> when given oral doses approximately 30 times MRHD for only five to seven days.</p>
<p>In the two-year rat study, irreversible and progressive variations in the caliber of retinal vessels (focal sacculations and constrictions) occurred at all dose levels (7 to 200 times MRHD) in a dose-related fashion. The effect was first observed in the 88th week of dosing, with a progressively increased incidence thereafter, even after cessation of dosing.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6934c93-1a4a-4eda-8187-7aeaa9fb6130"></a><a name="section-6.9"></a><p></p>
<h2>Pregnancy Categories C (first trimester) and D (second and third trimesters)</h2>
<p class="First"><span class="Bold">See <a href="#i4i_section_id_fetal">WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality.</a></span></p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_0851e60c-e5af-46d8-99d7-07d060a9b449"></a><a name="section-6.10"></a><p></p>
<h2>Pregnancy–Nonteratogenic Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bceeef3e-7909-469e-ba2d-021e8a59718a"></a><a name="section-6.10.1"></a><p></p>
<h3><span class="Bold">Hydrochlorothiazide</span></h3>
<p class="First">Thiazides cross the placental barrier and appear in cord blood. The use of thiazides in pregnant women requires that the anticipated benefit be weighed against possible hazards to the fetus. These hazards include fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in the adult.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_ffc7db75-2d7a-46e9-a4c6-48cc0afaac9c"></a><a name="section-6.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Both captopril and hydrochlorothiazide are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from both drugs, a decision should be made whether to discontinue nursing or to discontinue therapy taking into account the importance of Captopril and Hydrochlorothiazide to the mother. (See <a href="#i4i_pediatric_use_id_pediatric">PRECAUTIONS: Pediatric Use</a>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_pediatric"></a><a name="section-6.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. There is limited experience reported in the literature with the use of captopril in the pediatric population; dosage, on a weight basis, was generally reported to be comparable to or less than that used in adults.</p>
<p>Infants, especially newborns, may be more susceptible to the adverse hemodynamic effects of captopril. Excessive, prolonged and unpredictable decreases in blood pressure and associated complications, including <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, have been reported.</p>
<p>Captopril and Hydrochlorothiazide should be used in pediatric patients only if other measures for controlling blood pressure have not been effective.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6c620576-f99f-40cc-b310-1ec4aa4f8e60"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_55ffcc5f-48f4-44b7-ba9d-da4528f688c8"></a><a name="section-7.1"></a><p></p>
<h2>Captopril</h2>
<p class="First">Reported incidences are based on clinical trials involving approximately 7000 patients.</p>
<p><span class="Bold"><span class="Italics">Renal</span></span>: About one of 100 patients developed <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>).</p>
<p>Each of the following has been reported in approximately 1 to 2 of 1000 patients and are of uncertain relationship to drug use: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic</span></span>: <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> has occurred (see <a href="#i4i_warnings_id_warnings">WARNINGS</a>). Cases of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> have been reported.</p>
<p><span class="Bold"><span class="Italics">Dermatologic</span></span>: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, often with <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and sometimes with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, occurred in about 4 to 7 (depending on renal status and dose) of 100 patients, usually during the first four weeks of therapy. It is usually maculopapular, and rarely urticarial. The <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is usually mild and disappears within a few days of dosage reduction, short-term treatment with an antihistaminic agent, and/or discontinuing therapy; remission may occur even if captopril is continued. <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, without <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, occurs in about 2 of 100 patients. Between 7 and 10 percent of patients with <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> have shown <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and/or positive ANA titers. A reversible associated <span class="product-label-link" type="condition" conceptid="139899" conceptname="Pemphigoid">pemphigoid</span>-like lesion, and <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, have also been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> has been reported in 2 to 5 of 1000 patients.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular</span></span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may occur; see <a href="#i4i_warnings_id_warnings">WARNINGS</a> and <a href="#i4i_interactions_id_interactions">PRECAUTIONS (Drug Interactions)</a> for discussion of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with captopril therapy.</p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> have each been observed in approximately 1 of 100 patients.</p>
<p><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">Angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, Raynaud's syndrome, and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have each occurred in 2 to 3 of 1000 patients.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></span></span>: Approximately 2 to 4 (depending on renal status and dose) of 100 patients developed a diminution or <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span> perception. Taste impairment is reversible and usually self-limited (2 to 3 months) even with continued drug administration. <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> may be associated with the <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">loss of taste</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> involving the extremities, face, lips, mucous membranes, tongue, glottis or larynx has been reported in approximately one in 1000 patients. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> involving the upper airways has caused fatal airway obstruction. (See <a href="#i4i_section_id_neck">WARNINGS: Captopril: Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a> and <a href="#i4i_section_id_intestinal">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a> and <a href="#i4i_info_patients_id_information">PRECAUTIONS: Information for Patients</a>).</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></span>: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> has been reported in 0.5 to 2% of patients treated with captopril in clinical trials (see <a href="#i4i_section_id_cough">PRECAUTIONS: General: Captopril: <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></a>).</p>
<p>The following have been reported in about 0.5 to 2 percent of patients but did not appear at increased frequency compared to placebo or other treatments used in controlled trials: <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous ulcers</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>.</p>
<p>Other clinical adverse effects reported since the drug was marketed are listed below by body system. In this setting, an incidence or causal relationship cannot be accurately determined.</p>
<p><span class="Bold"><span class="Italics">Body as a Whole:</span></span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> (see WARNINGS: Captopril: Anaphylactoid and Possibly Related Reactions and <a href="#i4i_section_id_hemodialysis">PRECAUTIONS: Hemodialysis</a>).</p>
<p><span class="Bold"><span class="Italics">General:</span></span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>/insufficiency, rhythm disturbances, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold"><span class="Italics">Dermatologic:</span></span> bullous <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>.</p>
<p><span class="Bold"><span class="Italics">Gastrointestinal:</span></span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, including aplastic and hemolytic.</p>
<p><span class="Bold"><span class="Italics">Hepatobiliary:</span></span> <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, including rare cases of <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>.</p>
<p><span class="Bold"><span class="Italics">Metabolic:</span></span> symptomatic <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Bold"><span class="Italics">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>.</p>
<p><span class="Bold"><span class="Italics">Nervous/Psychiatric:</span></span> <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p><span class="Bold"><span class="Italics">Respiratory:</span></span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p><span class="Bold"><span class="Italics">Special Senses:</span></span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p><span class="Bold"><span class="Italics">Urogenital:</span></span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<p>As with other ACE inhibitors, a syndrome has been reported which may include: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other dermatologic manifestations, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> and an elevated ESR.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fad87e00-e9f2-48e1-bd5a-074ebe7a754a"></a><a name="section-7.2"></a><p></p>
<h2>Fetal/Neonatal Morbidity and Mortality</h2>
<p class="First"><span class="Bold"> See <a href="#i4i_section_id_fetal">WARNINGS: Captopril: Fetal/Neonatal Morbidity and Mortality</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0114fad-505f-4bc0-b90d-a657da47f01d"></a><a name="section-7.3"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First"><span class="Bold"><span class="Italics">Gastrointestinal System:</span></span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, cramping, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>.</p>
<p><span class="Bold"><span class="Italics">Central Nervous System:</span></span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>.</p>
<p><span class="Bold"><span class="Italics">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>; <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
<p><span class="Bold"><span class="Italics">Other:</span></span> <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, and transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.</p>
<p>Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_altered"></a><a name="section-7.4"></a><p></p>
<h2>Altered Laboratory Findings</h2>
<p class="First"><span class="Bold"><span class="Italics">Serum Electrolytes:</span></span> <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>: small increases in serum potassium, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <a href="#i4i_section_id_captopril">PRECAUTIONS: Captopril</a>).</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span>:</span></span> particularly in patients receiving a low sodium diet or concomitant diuretics.</p>
<p><span class="Bold"><span class="Italics">BUN/Serum Creatinine:</span></span> Transient elevations of BUN or serum creatinine especially in volume or salt depleted patients or those with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span> may occur. Rapid reduction of longstanding or markedly elevated blood pressure can result in decreases in the glomerular filtration rate and, in turn, lead to increases in BUN or serum creatinine.</p>
<p><span class="Bold"><span class="Italics">Hematologic:</span></span> A positive ANA has been reported.</p>
<p><span class="Bold"><span class="Italics">Liver Function Tests:</span></span> Elevations of liver transaminases, alkaline phosphatase, and serum bilirubin have occurred.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_7b4fbf25-d894-4893-9ff1-5cc74cfee2e9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7dc25aa9-e947-411e-8ce6-2af05cac08f5"></a><a name="section-8.1"></a><p></p>
<h2>Captopril</h2>
<p class="First">Correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> would be of primary concern. Volume expansion with an intravenous infusion of normal saline is the treatment of choice for restoration of blood pressure.</p>
<p>While captopril may be removed from the adult circulation by hemodialysis, there is inadequate data concerning the effectiveness of hemodialysis for removing it from the circulation of neonates or children. Peritoneal dialysis is not effective for removing captopril; there is no information concerning exchange transfusion for removing captopril from the general circulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e05f47bf-b302-4eb8-811f-549d83c62fa5"></a><a name="section-8.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">In addition to the expected <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, overdosage of thiazides may produce varying degrees of <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> which may progress to <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> within a few hours, with minimal <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration and cardiovascular function and without evidence of serum electrolyte changes or <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. The mechanism of thiazide-induced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span> is unknown. <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">Gastrointestinal irritation</span> and hypermotility may occur. Transitory increase in BUN has been reported, and serum electrolyte changes may occur, especially in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
<p>In addition to gastric lavage and supportive therapy for <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, symptomatic treatment of gastrointestinal effects may be needed. The degree to which hydrochlorothiazide is removed by hemodialysis has not been clearly established. Measures as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function should be instituted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_administration"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE MUST BE INDIVIDUALIZED ACCORDING TO PATIENT'S RESPONSE.</p>
<p>Captopril and Hydrochlorothiazide tablets may be substituted for the previously titrated individual components.</p>
<p>Alternatively, therapy may be instituted with a single tablet of Captopril and Hydrochlorothiazide 25 mg/15 mg taken once daily. For patients insufficiently responsive to the initial dose, additional captopril or hydrochlorothiazide may be added as individual components or by using Captopril and Hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg or 50 mg/25 mg, or divided doses may be used.</p>
<p>Because the full effect of a given dose may not be attained for 6 to 8 weeks, dosage adjustments should generally be made at 6 week intervals, unless the clinical situation demands more rapid adjustment.</p>
<p>In general, daily doses of captopril should not exceed 150 mg and of hydrochlorothiazide should not exceed 50 mg.</p>
<p>Captopril and Hydrochlorothiazide tablets should be taken one hour before meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f6d8b47-25c0-4867-bf23-8adfe22c04d0"></a><a name="section-9.1"></a><p></p>
<h2>Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Because captopril and hydrochlorothiazide are excreted primarily by the kidneys, excretion rates are reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. These patients will take longer to reach steady-state captopril levels and will reach higher steady-state levels for a given daily dose than patients with normal renal function. Therefore, these patients may respond to smaller or less frequent doses of Captopril and Hydrochlorothiazide.</p>
<p>After the desired therapeutic effect has been achieved, the dose intervals should be increased or the total daily dose reduced until the minimal effective dose is achieved. When concomitant diuretic therapy is required in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, a loop diuretic (e.g., furosemide), rather than a thiazide diuretic is preferred for use with captopril; therefore, for patients with severe renal dysfunction the captopril-hydrochlorothiazide combination tablet is not usually recommended. (See <a href="#i4i_section_id_membrane">WARNINGS: Captopril: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure</a> and <a href="#i4i_section_id_hemodialysis">PRECAUTIONS: Hemodialysis</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_7ead0b7a-24ed-49dc-81e9-a42639307d59"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Captopril and Hydrochlorothiazide Tablets, USP 25 mg/15 mg are supplied as white, round, quadrisected, biconvex tablets containing 25 mg of captopril and 15 mg of hydrochlorothiazide. The tablet is debossed with <span class="Bold">M 81</span> on one side and is quadrisected on the reverse side. They are available as follows:</p>
<p>NDC 0378-0081-01<br>bottles of 100 tablets</p>
<p>Captopril and Hydrochlorothiazide Tablets, USP 25 mg/25 mg are supplied as peach, round, quadrisected, biconvex, tablets containing 25 mg of captopril and 25 mg of hydrochlorothiazide. The tablet is debossed with <span class="Bold">M 83</span> on one side and is quadrisected on the reverse side. They are available as follows:</p>
<p>NDC 0378-0083-01<br>bottles of 100 tablets</p>
<p>Captopril and Hydrochlorothiazide Tablets, USP 50 mg/15 mg are supplied as white, partially bisected, biconvex, capsule shaped tablets containing 50 mg of captopril and 15 mg of hydrochlorothiazide. The tablet is debossed with <span class="Bold">M 84</span> on one side and is partially bisected on both sides. They are available as follows:</p>
<p>NDC 0378-0084-01<br>bottles of 100 tablets</p>
<p>Captopril and Hydrochlorothiazide Tablets, USP 50 mg/25 mg are supplied as peach, partially bisected, biconvex, capsule shaped tablets containing 50 mg of captopril and 25 mg of hydrochlorothiazide. The tablet is debossed with <span class="Bold">M 86</span> on one side and is partially bisected on both sides. They are available as follows:</p>
<p>NDC 0378-0086-01<br>bottles of 100 tablets</p>
<p>Dispense in a tight, light-resisitant container as defined in the USP using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.] Protect from moisture.</span></p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED MARCH 2006<br>CPHZ:R7</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_18db176a-a408-4b2c-b5bc-60fd8358723d"></a><a name="section-11"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/15 mg</span></p>
<p><span class="Bold">NDC</span><span class="Bold">0378-0081-01</span></p>
<p><span class="Bold">Captopril and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span></p>
<p><span class="Bold">25 mg/</span><br><span class="Bold">15 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Captopril, USP <span class="Bold">          </span>25 mg<br>Hydrochlorothiazide, USP <span class="Bold">          </span>15 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from moisture.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0081A5</span></p>
<div class="Figure">
<a name="id1518"></a><img alt="Captopril and Hydrochlorothiazide Tablets, USP 25 mg/15 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d826812e-ede7-49e7-8384-29ec5b142ef3&amp;name=1ce0ed86-6073-4983-86bf-6d022e27ce7e-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9675cf53-1c8e-4638-9395-cdf1abe5628c"></a><a name="section-12"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 25 mg/25 mg</span></p>
<p><span class="Bold">NDC 0378-0083-01</span></p>
<p><span class="Bold">Captopril and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span></p>
<p><span class="Bold">25 mg/</span><br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Captopril, USP <span class="Bold">           </span>25 mg<br>Hydrochlorothiazide, USP <span class="Bold">          </span>25 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from moisture.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0083A5</span></p>
<div class="Figure">
<a name="id1581"></a><img alt="Captopril and Hydrochlorothiazide Tablets, USP 25 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d826812e-ede7-49e7-8384-29ec5b142ef3&amp;name=1ce0ed86-6073-4983-86bf-6d022e27ce7e-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b744fb87-268b-4897-87e4-ee4de6f31d10"></a><a name="section-13"></a><p></p>
<h1> </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg/15 mg</span></p>
<p><span class="Bold">NDC</span><span class="Bold">0378-0084-01</span></p>
<p><span class="Bold">Captopril and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span></p>
<p><span class="Bold">50 mg/</span><br><span class="Bold">15 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Captopril, USP <span class="Bold">           </span>50 mg<br>Hydrochlorothiazide, USP <span class="Bold">         </span>15 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from moisture.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0084A5</span></p>
<div class="Figure">
<a name="id1644"></a><img alt="Captopril and Hydrochlorothiazide Tablets, USP 50 mg/15 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d826812e-ede7-49e7-8384-29ec5b142ef3&amp;name=1ce0ed86-6073-4983-86bf-6d022e27ce7e-04.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_da40992f-480a-49cf-a945-7a70cb855d2c"></a><a name="section-14"></a><p></p>
<h1>  </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg/25 mg</span></p>
<p><span class="Bold">NDC</span><span class="Bold">0378-0086-01</span></p>
<p><span class="Bold">Captopril and</span><br><span class="Bold">Hydrochlorothiazide</span><br><span class="Bold">Tablets, USP</span></p>
<p><span class="Bold">50 mg/</span><br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only      100 Tablets</span></p>
<p>Each tablet contains:<br>Captopril, USP <span class="Bold">          </span>50 mg<br>Hydrochlorothiazide, USP <span class="Bold">          </span>25 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p><span class="Bold">Keep this and all medication</span><br><span class="Bold">out of the reach of children.</span></p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).</span><br><span class="Bold">[See USP Controlled Room</span><br><span class="Bold">Temperature.]</span></p>
<p><span class="Bold">Protect from moisture.</span></p>
<p><span class="Bold">Usual Adult Dosage: </span>See accom-<br>panying prescribing information.</p>
<p><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p><span class="Bold">RM0086A5</span></p>
<div class="Figure">
<a name="id1707"></a><img alt="Captopril and Hydrochlorothiazide Tablets, USP 50 mg/25 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d826812e-ede7-49e7-8384-29ec5b142ef3&amp;name=1ce0ed86-6073-4983-86bf-6d022e27ce7e-05.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAPTOPRIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">captopril and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0081</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPTOPRIL</strong> (CAPTOPRIL) </td>
<td class="formItem">CAPTOPRIL</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;81</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0081-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074896</td>
<td class="formItem">12/29/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAPTOPRIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">captopril and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0083</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPTOPRIL</strong> (CAPTOPRIL) </td>
<td class="formItem">CAPTOPRIL</td>
<td class="formItem">25 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">4 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;83</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0083-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074896</td>
<td class="formItem">12/29/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAPTOPRIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">captopril and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0084</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPTOPRIL</strong> (CAPTOPRIL) </td>
<td class="formItem">CAPTOPRIL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;84</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0084-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074896</td>
<td class="formItem">12/29/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAPTOPRIL AND HYDROCHLOROTHIAZIDE 		
					</strong><br><span class="contentTableReg">captopril and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-0086</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAPTOPRIL</strong> (CAPTOPRIL) </td>
<td class="formItem">CAPTOPRIL</td>
<td class="formItem">50 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE (peach) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;86</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-0086-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074896</td>
<td class="formItem">12/29/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Phamaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3f830175-e2d8-410d-b25a-49e4cc3c97e4</div>
<div>Set id: d826812e-ede7-49e7-8384-29ec5b142ef3</div>
<div>Version: 6</div>
<div>Effective Time: 20060315</div>
</div>
</div> <div class="DistributorName">Mylan Phamaceuticals Inc.</div></p>
</body></html>
